Regarding: “The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial”

[...]the authors should provide the information regarding the primary outcome which was used for calculating the sample size and the magnitude of the difference that the study was designed to detect. [...]n3-PUFAs might not improve the outcome two weeks after the start of the intervention. [...]the results of a modified intention-to-treat analysis which includes data on the participants who withdrew after randomization (because of no indication for enteral feeding), the results might provide more useful knowledge for clinicians to evaluate the true effects of n3-PUFAs in an actual clinical setting.